Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent Type in Patients With ST-Segment Elevation Myocardial Infarction Randomized to Bare Metal or Drug-Eluting Stenting During Primary Percutaneous Coronary Intervention

Schoos, Mikkel Malby; Kelbæk, Henning; Kofoed, Klaus F.; Køber, Lars; Kløvgaard, Lene; Helqvist, Steffen; Engstrøm, Thomas; Saunamäki, Kari; Jørgensen, Erik; Holmvang, Lene; Clemmensen, Peter

doi:10.1016/j.amjcard.2011.01.042

Cited by 27 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 Many studies have reported that the level of CRP is closely related to the occurrence of adverse cardiovascular events. [27][28][29] The result of this meta-analysis showed that in the patients using interleukin-1 blockade treatment, the level of CRP has been significantly decreased. Several studies have reported the effectiveness of interleukin-1 blocker used in treatment in diabetes.…”

Section: Discussionmentioning

confidence: 93%

Retracted: Interleukin‐1 blockade treatment decreasing cardiovascular risk

Zheng

Zeng

Nie

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Retracted: Interleukin‐1 blockade treatment decreasing cardiovascular risk

Zheng

Zeng

Nie

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

“…204 studies were excluded because they did not meet the inclusion criteria: 2 studies were presented as abstracts, 39 studies did not evaluate PPCI, 109 studies contained mixed populations or other coronary syndromes except for STEMI, 5 studies determined CRP after revascularization or provided no CRP cut-off, 47 studies presented no CRP-outcomes correlation, one study did have a follow-up under 6 months and one study was in Chinese. Consequently, 7 studies were included in our meta-analysis, 6 retrospective studies 26 27 28 29 30 31 and 1 prospective cohort study 32 . The study selection process is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis

Mincu

Jánosi

Vinereanu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Risk assessment in patients with acute coronary syndromes (ACS) is critical in order to provide adequate treatment. We performed a systematic meta-analysis to assess the predictive role of serum C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction (STEMI), treated with primary percutaneous coronary intervention (PPCI). We included 7 studies, out of 1,033 studies, with a total of 6,993 patients with STEMI undergoing PPCI, which were divided in the high or low CRP group, according to the validated cut-off values provided by the corresponding CRP assay. High CRP values were associated with increased in-hospital and follow-up all-cause mortality, in-hospital and follow-up major adverse cardiac events (MACE), and recurrent myocardial infarction (MI). The pre-procedural CRP predicted in-hospital target vessel revascularization (TVR), but was not associated with acute/subacute and follow-up in-stent restenosis (ISR), and follow-up TVR. Thus, pre-procedural serum CRP could be a valuable predictor of global cardiovascular risk, rather than a predictor of stent-related complications in patients with STEMI undergoing PPCI. This biomarker might have the potential to improve the management of these high-risk patients.

show abstract

“…This study also reported that a high level of hs-CRP is associated with the development of contrast-induced nephropathy. Schoos et al 25) have evaluated the higher level of hs-CRP (>2 mg/L) and type of stent as predictors of long-term prognosis. The results of this study indicate that a higher level of hs-CRP is a more important predictor in STEMI patients treated by a bare-metal stent than in those treated by a drug-eluting stent, and a bare-metal stent should then be preferred when hs-CRP <2 mg/L, and a drug-eluting stent when hs-CRP >2 mg/L, in order to decrease long-term adverse outcomes, including stent thrombosis.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention

Kim

Kang

et al. 2013

Korean Circ J

View full text Add to dashboard Cite

Background and ObjectivesThe high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation, has been known to be elevated in patients with coronary artery disease. However, there is controversy about the predictive value of hs-CRP after acute myocardial infarction (MI). Therefore, we evaluated the impact of ischemic time on the predictive value of hs-CRP in ST-segment elevation myocardial infarction (STEMI) patients who were treated by primary percutaneous coronary intervention (PCI).Subjects and MethodsWe enrolled 5123 STEMI patients treated by primary PCI from the Korean Working Group in Myocardial Infarction and divided enrolled patients into four groups by symptom-to-balloon time (SBT) and level of hs-CRP (Group I: SBT <6 hours and hs-CRP <3 mg/L, Group II: SBT <6 hours and hs-CRP ≥3 mg/L, Group III: SBT ≥6 hours and hs-CRP <3 mg/L, and Group IV: SBT ≥6 hours and hs-CRP ≥3 mg/L). To evaluate the impact of ischemic time on the predictive value of hs-CRP in STEMI patients, we compared the cumulative cardiac event-free survival rate between these four groups.ResultsThe sum of the cumulative incidence of all-cause mortality and recurrence of MI was higher in Group IV than in the other groups. However, there was no significant difference among Group I, Group II, and Group III. The Cox-regression analyses showed that an elevated level of hs-CRP (≥3 mg/L) was an independent predictor of long-term cardiovascular outcomes only among late-presenting STEMI patients (p=0.017, hazard ratio=2.462).ConclusionFor STEMI patients with a long ischemic time (≥6 hours), an elevated level of hs-CRP is a poor prognostic factor of long-term cardiovascular outcomes.

show abstract

Cited by 27 publications

References 26 publications

Retracted: Interleukin‐1 blockade treatment decreasing cardiovascular risk

Retracted: Interleukin‐1 blockade treatment decreasing cardiovascular risk

Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis

The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention

Contact Info

Product

Resources

About